Irinotecan
- Generic Name
- Irinotecan
- Brand Names
- Camptosar, Onivyde, Onivyde pegylated liposomal (previously known as Onivyde)
- Drug Type
- Small Molecule
- Chemical Formula
- C33H38N4O6
- CAS Number
- 97682-44-5
- Unique Ingredient Identifier
- 7673326042
- Background
Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cell death. It is a derivative of camptothe...
- Indication
For the treatment of metastatic colorectal cancer (first-line therapy when administered with 5-fluorouracil and leucovorin). Also used in combination with cisplatin for the treatment of extensive small cell lung cancer. Irinotecan is currently under investigation for the treatment of metastatic or recurrent cervical cancer. Also used in combination with fluo...
- Associated Conditions
- Esophageal Cancer, Ewing's Sarcoma, Gastric Cancer, High Grade Glioma: Glioblastoma (GBM), Metastatic Cervical Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Cancer, Rhabdomyosarcomas, Small Cell Lung Cancer (SCLC), Stage IV Colorectal Cancer, Recurrent, metastatic Colorectal carcinoma, Refractory, metastatic Pancreatic adenocarcinoma
- Associated Therapies
- -
GENOCARE: a Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual Care
- First Posted Date
- 2022-05-25
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Reema A. Patel
- Target Recruit Count
- 178
- Registration Number
- NCT05391126
- Locations
- 🇺🇸
University of Kentucky, Lexington, Kentucky, United States
A Study to Compare Onivyde Manufactured at Two Different Production Sites in Adult Participants With Advanced Cancer in the Pancreas
- Conditions
- Interventions
- First Posted Date
- 2022-05-20
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 177
- Registration Number
- NCT05383352
- Locations
- 🇫🇷
Institut BERGONIE Centre de Lutte Contre le Cancer, Bordeaux, France
🇦🇺Flinders Medical Centre, Bedford Park, Australia
🇦🇺Peninsula and Southeast Oncology - Frankston Private Hospital, Frankston, Australia
Metronomic Chemotherapy in Wilms Tumor (MetroWilms-1906)
- Conditions
- Interventions
- First Posted Date
- 2022-05-20
- Last Posted Date
- 2023-10-16
- Lead Sponsor
- Centre Oscar Lambret
- Target Recruit Count
- 28
- Registration Number
- NCT05384821
- Locations
- 🇫🇷
CHU de MONTPELLIER - Hôpital Arnaud de Villeneuve, Montpellier, France
🇫🇷Centre Léon Bérard, Lyon, France
🇫🇷CHRU NANCY - Hôpital d'Enfants, Vandœuvre-lès-Nancy, France
A Study of AK112 With or Without AK117 in Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-05-19
- Last Posted Date
- 2024-02-06
- Lead Sponsor
- Akeso
- Target Recruit Count
- 104
- Registration Number
- NCT05382442
- Locations
- 🇨🇳
The Sixth Hospital,Sun Yat-sen University, Guanzhou, Guangdong, China
A Study of ASP3082 in Adults With Advanced Solid Tumors
- First Posted Date
- 2022-05-19
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 541
- Registration Number
- NCT05382559
- Locations
- 🇺🇸
Florida Cancer Specialist, Lake Mary, Florida, United States
🇺🇸Case Western, Cleveland, Ohio, United States
🇺🇸University of Wisconsin Hospital, Madison, Wisconsin, United States
A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-05-18
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 225
- Registration Number
- NCT05379595
- Locations
- 🇺🇸
O Neal Comprehensive Cancer Center at UAB, Birmingham, Alabama, United States
🇺🇸University of Southern California, Los Angeles, California, United States
🇺🇸University of California, Los Angeles UCLA, Los Angeles, California, United States
Concomitant Intraperitoneal and Systemic Chemotherapy in Patients With Extensive Peritoneal Carcinomatosis of Gastric Origin
- Conditions
- Interventions
- First Posted Date
- 2022-05-18
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- Erasmus Medical Center
- Target Recruit Count
- 20
- Registration Number
- NCT05379790
- Locations
- 🇳🇱
Erasmus MC, Rotterdam, Zuid-Holland, Netherlands
🇳🇱Catharina Hospital, Eindhoven, Netherlands
A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer
- First Posted Date
- 2022-05-09
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 305
- Registration Number
- NCT05365581
- Locations
- 🇰🇷
Site KR82003, Seocho-gu, Seoul, Korea, Republic of
🇰🇷Site KR82005, Seodaemun-gu, Seoul, Korea, Republic of
🇰🇷Site KR82001, Guro-gu, Seoul, Korea, Republic of
A Study of Combination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer (MK-3475-06A)
- Conditions
- Interventions
- First Posted Date
- 2022-04-22
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 120
- Registration Number
- NCT05342636
- Locations
- 🇧🇷
ICESP - INSTITUTO DO CÂNCER DO ESTADO DE SÃO PAULO ( Site 2300), São Paulo, Sao Paulo, Brazil
🇫🇷Hopital Claude Huriez - CHU de Lille ( Site 1100), Lille, Nord, France
🇫🇷Centre Hospitalier Régional Universitaire de Brest - Hôpital Morvan ( Site 1104), Brest, Finistere, France
Study of Magrolimab Given Together With FOLFIRI/BEV in Patients With Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC)
- Conditions
- Interventions
- First Posted Date
- 2022-04-15
- Last Posted Date
- 2024-07-23
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 77
- Registration Number
- NCT05330429
- Locations
- 🇺🇸
Fort Wayne Medical Oncology and Hematology, Inc., Fort Wayne, Indiana, United States
🇺🇸Virginia Cancer Specialists, PC, Arlington, Virginia, United States
🇺🇸Seattle Cancer Care Alliance (SCCA), Seattle, Washington, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.